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Abstract Patients infected with human immunodeficiency
virus (HIV) have a higher risk of developing major depressive
disorder (MDD) than the general population. Immunophilins
FKBP51 and FKBP52 are expressed in cortical neurons and
regulate the function of the glucocorticoid receptor (GR).
Previous reports have shown that genetic variants in the
FKBP5 gene encoding FKBP51 are linked to psychiatric
disorders. We sought to determine whether immunophilins
are upregulated in HIV infection. To determine whether
FKBP52 and FKBP51 are associated with MDD and/or HIV,
we compared protein and gene expression in autopsy tissues
from the frontal cortical gray matter. The study cases were
divided into five groups: control, MDD, MDD with
psychosis, HIV+, and HIV+ with MDD. Gene expression
and protein levels were determined by real-time PCR and
Western blot analysis of fresh frozen tissues. Genotyping of
previously published alleles of the FKBP5 gene was also
performed. We found correlation of upregulation of both
immunophilins in the HIV-infected groups. In the HIV+
population with MDD, FKBP4 expression is significantly
higher while FKBP5 is more variable. After analyzing the
FKBP5 gene for single nucleotide polymorphisms, we found
that rs3800373 CC genotype is more frequent in the MDD
and MDD/Psychosis groups. We hypothesized that the
levels of FKBP51, as modulator of the nuclear translocation
of GR, would be lower in MDD. Instead, an increase in
FKBP51 at both the transcript (FKBP5) and protein level
correlated with MDD. Increased FKBP4 expression of
correlated to HIV+MDD but not to HIV without MDD.
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Introduction
Immunophilins are a class of chaperone and adapter proteins
widely expressed in most tissues, particularly abundant in the
brain, specifically in neurons (Steiner et al. 1992; Sinars et al.
2003). FKBP52 and FKBP51 are the products of the FKBP4
and FKBP5 genes, respectively. FKBP52 functions as an
adapter protein within the glucocorticoid receptor (GR) and
HSP90 complex that links the hormone-bound receptor
complex to the molecular motor dynein allowing for
shuttling of the activated receptor complex to the nucleus
(Wochnik et al. 2005). In contrast to FKBP52, the FK506-
binding domain of FKBP51 lacks isomerase function, but is
shown to bind the GR through the tetratricopeptide repeat
domains and therefore functions as a competitive inhibitor to
formation of the GR-FKBP52–dynein complex (Denny et al.
2000; Westberry et al. 2006). Sapolsky’s glucocorticoid-
cascade hypothesis proposes a feed-forward mechanism of
decreased feedback inhibition with increased sensitivity of
the brain to cortisol (Sapolsky and Plotsky 1990). The action
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of the GR in the brain may be central to the molecular
mechanism whereby the hypothalamo–pituitary–adrenal axis
feedback loop is dysregulated in hypercortisolemia observed
in depression (Sapolsky and Plotsky 1990; Garcia et al.
2004). Therefore, the modulation of GR signaling in the
cortex of the brain may be a level of regulation that could
affect the susceptibility of neurons to lose synaptic and
dendritic density found in hypercortisolemia and depression
(Cotter et al. 2002a, b).
Single nucleotide polymorphisms (SNPs) in the FKBP5
gene have been associated with MDD, posttraumatic stress
disorder, treatment response to drugs, and delayed recovery
from psychosocial stress in healthy adults (Binder et al.
2004, 2008; Ising et al. 2008; Lekman et al. 2008). The
specific molecular consequences of these SNPs are not
known. Binder et al. identified two polymorphisms that link
to decreased FKBP51 protein levels in the blood (Binder et
al. 2004). The same polymorphisms in FKBP5 were linked
with peritraumatic dissociation in medically injured children
(Koenen et al. 2005). However, one prospective study failed
to definitively assign the designated SNPs’ associations with
MDD and affective disorder (Gawlik et al. 2006). FKBP5
may play a role only in some depression cases, with other
genes involved in the glucocorticoid system responsible for
disturbances of the HPA axis during depressive episodes.
Since the prevalence of major depressive disorder
(MDD) is significantly elevated in individuals infected
with HIV, we sought to determine whether there was a
relationship between HIV infection, MDD, and the expres-
sion of immunophilins in the frontal cortex (Reiter 2000;
Valente 2003; Porche and Willis 2006). We have previously
showed an increase of the related immunophilin FKBP12 in
the deep gray matter of HIV patients, which we hypothe-
sized to be a protective response (Christeff et al. 1997; Bing
et al. 2001; Valente 2003; Porche and Willis 2006).
Materials and methods
Demographic information
Autopsy fresh frozen brain tissues were kindly provided by
the Stanley Foundation and the California NeuroAIDS
Tissue Network (CNTN). Twelve cases from each group
were studied with an age range of 24–63 years. The cases
were divided into five study groups: control, MDD, MDD
with psychosis, HIV+, and HIV+ with MDD (Table 1). The
cause of death in the control group was mainly cardiac
arrest, while in the depressed groups, the cause of death
was predominantly suicide. The cause of death for the two
HIV groups was AIDS-associated complications. The
postmortem interval (PMI) was generally within 24 h (the
average in the CNTN cohort was approximately 12 and
35 h for the Stanley Foundation cohort). One subject in the
HIV/MDD group was diagnosed with HIV-associated
dementia (HAD), no. 49, and two subjects in the HIV
group were diagnosed with minor cognitive and motor
deficit (MCMD), subjects no. 41 and no. 45.
FKBP4 and FKBP5 gene expression
For RNA isolation, 100 mg was homogenized in ice-cold
TRIzol reagent (Invitrogen) following manufacturer’s instruc-
tions. RNA quality was assessed by the A260/A280 ratio and
by agarose electrophoresis. CDNA synthesis was performed
using 1 μg of RNA using the SuperScript III kit from
Invitrogen. For quantitative PCR, 40 ng cDNA per reaction
was used, and FAM-labeled 20× prevalidated probes were
purchased from Applied Biosystems. For FKBP5, assay
Hs00188025_m1; for FKBP4, assay Hs00427038_g1; and
for GAPDH, assay Hs02758991_g was used. TaqMan master
mix (2×) purchased from Applied Biosystems was used in
20 μL reactions on 96 well plates, and assays were
performed at the University of California San Diego Center
for AIDS Research Genomics Core. Gene expression is
reported as fold control versus the median of the control
group using the ΔΔ-CT method comparing to housekeeping
gene GAPDH whereby ΔCT = CTGAPDH − CTGene, ΔΔCT =
ΔCTControl − ΔCTDisease, and Fold Control ¼ 2ΔΔCT. A
test for normality showed that not all groups are distributed
in a Normal curve; therefore, nonparametric statistical
analyses were performed, and Kruskal–Wallace rank sums
test and Dunn’s multiple comparison were done using
Graphpad Prism software to compare the groups.
FKBP52 and FKBP51 protein analysis
For protein extraction, 100 mg of frozen brain tissue was cut
and homogenized in 0.9 mL ice-cold lysis buffer consisting of
50 mM Tris–HCl, 1% sodium dodecyl sulfate, 150 mMNaCl,
1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 μg/mL
aprotinin, 1mM sodiumNa3VO4, pH 7.4. Five micrograms of
total protein from each case was run in 10% polyacrylamide
gels and transferred to polyvinylfluoridine membranes.
Western blotting analysis for immunophilins FKBP52 and
FKBP51 was performed using primary antibodies incubated
overnight at 4°C: mouse anti-FKBP52 (Stressgen SRA1400)
at 1:5,000 and rabbit anti-FKBP51 (Abcam ab2901) at
1:1,000. Secondary antibodies were horseradish peroxidase-
conjugated donkey anti-mouse and donkey anti-rabbit
(Jackson Immunoresearch), respectively, at 1:5,000. The
chemiluminescence signal was developed according to
manufacturer’s protocols (Perkin Elmer NEL103001) and
quantified using densitometric analysis with Image J soft-
ware; changes are expressed as fold actin and normalized fold
actin.
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FKBP5 genotyping of patient cohort
Genotyping of previously published alleles of the FKBP5
gene implicated in mood disorders was performed. Genomic
DNA from the patients was isolated from the tissue
following manufacturer’s instructions of the DNeasy kit
(Qiagen no. 69504). Genotyping was performed using 20 ng
DNA following manufacturer’s protocols of the SNP
Genotyping Assay from Applied Biosystems: an A/C sub-
stitution in the 3′ untranslated region of FKBP5 gene, SNP
rs3800373, (Applied Biosystems Assay ID C_27489960_10),
and a C/T substitution in Intron 1 of the FKBP5 gene, SNP
rs1360780 (Applied Biosystems Assay ID C_8852038_10).
A five by three table was constructed of the possible
genotypes with the five test groups and Chi-square analysis
compared the expected genotype frequencies with observed.
Expected frequencies are determined by genotype frequency
in North American Caucasian population deposited in NCBI
SNP database; for rs3800373 record ID ss2334697 and for
rs1360780, record ID ss4777328 was used (Haga et al.
2002). Two by five tables were constructed and allelic




In order to determine whether age, PMI, and brain pH
were possible confounders, tests for correlation were
performed. Since gene expression is calculated as
Fold Change ¼ 2ΔΔCT, a value of 0.5 corresponds to a
Table 1 Demographic description of study groups
Patient ID Age Sex PMI pH Cause of
death
Control
1 48 M 12 6.51 Cardiac
2 24 M 17 6.6 MVA
3 50 F 35 6.31 Cardiac
4 44 M 27 6.82 AAP
5 35 M 31 6.59 MVA
6 63 M 40 6.91 Cardiac
7 50 M 11 6.5 Cardiac
8 63 M 37 6.5 Cardiac
9 34 M 9 6.56 MVA
10 56 F 29 6.78 Cardiac
11 56 F 31 6.66 Cardiac
12 39 F 24 6.88 Cardiac
Mean 46.8 25.3 6.64
MDD
13 32 F 19 6.8 Suicide
14 47 F 25 6.88 Suicide
15 56 M 38 6.59 Suicide
16 33 M 25 6.86 Suicide
17 45 F 29 6.9 Cardiac
18 24 M 21 6.61 Suicide
19 56 F 15 6.59 Suicide
20 44 M 24 6.52 Cardiac
21 34 M 24 6.79 Suicide
22 53 M 21 6.64 Cardiac
23 45 M 29 6.75 Suicide
24 45 F 13 6.58 Suicide
Mean 42.8 23.6 6.71
MDD psychosis
25 48 F 24 6.36 Suicide
26 40 M 52 6.48 OD
27 28 M 26 6.7 Suicide
28 28 F 40 6.68 Suicide
29 62 M 65 6.57 Suicide
30 28 F 40 6.68 Suicide
31 32 F 19 6.7 Suicide
32 63 M 31 6.6 Suicide
33 51 F 36 6.3 Unknown
34 40 F 49 6.72 Suicide
35 35 M 36 6.6 Suicide
36 36 F 32 6.74 PE
Mean 41.5 35.8 6.59
HIV+
38 45 M 12 AIDS
39 57 M 12 AIDS
40 35 M 5 AIDS
41 55 M 5 AIDS
42 57 M 12 AIDS
43 54 M 12 AIDS
44 49 M 10 AIDS
45 37 F 1 AIDS
46 40 M 10 AIDS
47 47 F 12 AIDS
48 46 M 12 AIDS
Mean 46.6 8.8
Table 1 (continued)
Patient ID Age Sex PMI pH Cause of
death
HIV+MDD
49 43 M 12 AIDS
50 43 M 31 AIDS
51 34 M 10 AIDS
52 55 M 120 AIDS
53 59 M 12 AIDS
54 54 M 11 AIDS
55 35 M 10 AIDS
56 38 M 7 AIDS
57 38 M 10 AIDS
58 39 M 12 AIDS
59 34 M 4 AIDS
Mean 44.7 15.2
PMI postmortem interval, MVA motor vehicle accident, AAP acute
alcohol poisoning, OD drug overdose, PE pulmonary embolism, AIDS
(complications due to) acquired immunodeficiency syndrome
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twofold decrease; therefore, a Log2 scale for the y-axis is
used so that 0.5 and 2 are equidistant from baseline;
regression analyses for correlation account for this. Expres-
sion was plotted versus age, PMI, and brain pH, and
Pearson’s test for correlation was performed. For all three
characteristics, there were no correlations with gene
expression, R<0.50.
In examining Table 1, one can see that the HIV+
specimen obtained from the CNTN had more males. The
HIV-negative groups obtained from the Stanley Foundation
had statistically indistinguishable male/female composi-
tions. t tests comparing expression in non-HIV males to
expression in non-HIV females of the two immunophilin
genes found no difference between the sexes with respect to
immunophilin expression, showing 95% confidence inter-
vals interquartile ranges. Since there was no difference
between male and female expression of FKBP4 (p=0.179)
and FKBP5 (p=0.716), sex is unlikely to be a confounder
to the analysis.
In order to represent the natural variation in the
population at large, fold control was calculated against the
median ΔCT value from the control group. Therefore, half
of the controls appear above and half below 1. As shown in
Fig. 1, the majority of patients in the two HIV+ populations
showed higher expression of FKBP4 and FKBP5 above the
control median. HIV+ patients exhibited a fold increase of
3.4±2.3 (mean ± 95% confidence interval), and HIV+MDD
patients exhibited a fold increase of 4.5±2.9 for the FKBP4
gene. HIV+ patients showed 4.0±2.3-fold increase over
control, and HIV+MDD patients showed 5.6±3.5-fold
increase over control for the FKBP5 gene. In the
HIV+MDD population, FKBP5 was more variable, ranging
from 0.7- to 12.0-fold change, while the HIV+ ranged from
1.4- to 6.3-fold increase. In MDD, MDD/Psyc, HIV, and
HIV/MDD, gene expression of both immunophilins is more
variable. In the HIV−MDD group, the trend is toward
increased expression of FKBP5 with median expression
1.7-fold higher than control; however, no change is
apparent for FKBP4 in the HIV−MDD population. For the
FKBP4 gene, HIV+ patients exhibited a fold increase of 3.2±
2.6 (mean ± standard deviation), and HIV+MDD patients
exhibited a fold increase of 3.1±3.3. For the FKBP5 gene,
HIV+ patients showed 13.5±15.8-fold increase over con-
trol, and HIV+MDD patients showed 9.6±12.7-fold in-
crease over control. In the HIV+MDD population, FKBP5
was more variable in the patient populations, ranging from
0.7- to 44.3-fold change in HIV+MDD and in HIV+ from
1.4- to 50-fold increase. In the HIV-negative MDD group,
Fig. 1 FKBP4 and FKBP5 expression is increased in HIV and HIV
with MDD. Gene expression in the cortical gray matter was
determined by qPCR using the ΔΔCT method and normalizing the
gene of interest to GAPDH expression. Fold-Control is plotted for
each of the study groups; circles represent individual patients, and
bars represent median within the group. Kruskal–Wallace rank sums
test with Dunn’s multiple comparison tested for significant difference
among the groups (*p<0.05)
Fig. 2 Correlation of FKBP4 and FKBP5 expression in frontal cortex
separated by group. Gene expression from the frontal cortex of
patients listed in Table 1 is determined by qPCR using the ΔΔCT
method and normalizing the gene of interest to GAPDH. Fold-Control
is plotted for each of the study group, plotting the FKBP4 expression
on the y-axis and FKBP5 expression on the x-axis for each individual
patient. For the control (circles, thick line) group, Pearson’s test for
correlation showed a correlation between FKBP4 and FKBP5 (R=
0.745). For the MDD (filled squares, black thin line) and MDD/Psych
(empty squares, black dashed line) groups, FKBP4 and FKBP5 were
not correlated (R=0.389 and −0.287). For both HIV (filled triangles,
gray thin line) and HIV/MDD (empty triangles, gray dashed line),
there was no correlation (R=−0.178 and −0.203, respectively)
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the trend is toward increased expression of FKBP5 with
median expression 2.4¬-fold higher than control; however,
no change is apparent for FKBP4 in this group. In
comparing HIV+ to HIV−, both FKBP4 and FKBP5 genes
are expressed at higher levels.
One subject was diagnosed with HAD, no. 49, and had
the lowest expression of FKBP4 in the HIV/MDD group,
0.14-fold of control and an increase in FKBP5, 4.6-fold of
control. Two subjects in the HIV group were diagnosed
with MCMD; subjects no. 41 and no. 45. Patient no. 41 had
the highest FKBP4 expression in the HIV group, 8.5-fold
for FKBP4 and 4.6-fold for FKBP5 over control. Patient
no. 45 was 2.7- and 1.4-fold over control for FKBP4 and
FKBP5, respectively. It is interesting that the patients with
cognitive impairment were outliers in some respects; the
only patient with HAD correlated with the lowest FKBP4
expressor in the HIV/MDD group, and one patient with
MCMD correlated to the highest FKBP4 expression in the
HIV group. These three subjects were not outliers in their
groups with respect to FKBP5 expression.
We also hypothesized that there would be a balance
between FKBP4 and FKBP5 expression, and the balance
would be disrupted in MDD, MDD/Psychosis, or HIV/
MDD. In Fig. 2, we plotted the FKBP4 expression on the y-
axis and FKBP5 on the x-axis and analyzed the possible
correlation in expression of the two genes, separating the
groups. Pearson’s test for correlation showed a correlation
between FKBP4 and FKBP5 (R=0.745) expression in the
control group (circles), which is absent in all other groups.
In the MDD (filled squares) and MDD/Psych (empty
squares) groups, no correlation was observed between
FKBP4 and FKBP5 (R=0.389 and −0.287, respectively).
Even though expression was elevated in both HIV (filled
triangles) and HIV/MDD (empty triangles), the correlation
Fig. 3 Expression of FKBP4 (a) and FKBP5 (b) in the CNTN groups
separated by most recent episode. Gene expression from frontal cortex
of patients for whom MDD clinical data were available is determined
by qPCR using the ΔΔCT method and normalizing the gene of
interest to GAPDH expression. Patients are divided based on MDD
episode within 1 month or within 6 months and Fold-Control plotted;
circles represent individuals, and bars represent median. Student’s t
test comparing the two groups’ expression showed a nonsignificant
trend based on most recent MDD episode for expression of FKBP4
p=0.11 (a) or FKBP5 p=0.15 (b)
Fig. 4 FKBP52 protein levels are increased in the HIV group. Cases
representing each study group were included in every gel. After
transfer and immobilization on PVDF membrane, proteins were
probed by Western blot for FKBP52; representative blot showed in
b. Membranes were stripped of antibodies and reprobed for actin.
Values are normalized to controls on their respective gels, Normalized
Fold-Actin = Fold-ActinPatient/Fold-ActinControlMean. The area within
the bar delineates the standard deviation about the mean (μ ± σ).
Kruskal–Wallace and Dunn’s multiple comparison test were used to
test for significance (*p<0.05; a)
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of the two genes observed in the control group was no
longer present when looking at the separate diagnostic
groups (R=−0.178 and −0.203).
In the tissue acquired from the CNTN, we had available
patient history of the MDD and MDD/Psych patients
regarding their most recent MDD ,episode and it was either
within the last month or 6 months before death. The FKBP4
and FKBP5 expression was higher in the MDD patients
who had MDD episodes within 1 month of death, but did
not reach statistical significance, p=0.11 and p=0.15,
respectively (Fig. 3).
Protein analysis
The protein analysis of FKBP52 and 51 illustrated in
Figs. 4 and 5, respectively, showed a wide variation in
expression of both immunophilins in the control group,
indicating that expression varies in the population at large
and likely is dependent on many factors. FKBP52 was
elevated in HIV Group compared to control patients, p=
0.0084. Compared to HIV without MDD, the HIV/MDD
group, although more variable than the control, had lower
levels of FKBP52. Amongst the MDD and MDD/Psychosis
Groups, expression of FKBP52 is more variable than
control, with the MDD mean above the standard deviation
of the mean control. FKBP51 showed higher mean protein
expression in the MDD, MDD/Psych, and HIV/MDD
groups, however, not statistically significant; there were
patients both above and below the standard deviation of the
control group.
Single nucleotide polymorphism analysis
Using the allelic discrimination assay, we tested two
polymorphisms: rs38000373, an A to C transversion
substitution in the 3′ untranslated region (3′UTR) of the
FKBP5 gene and rs1360780, which is a C to T transition
substitution in the second intron of the FKBP5 gene. The
rs1360780 polymorphism is located in a region where
transcription factors may bind, where hormone response
elements (HREs) are located as shown in Fig. 6, which may
alter transcription and have been implicated in mood
disorders (Hubler and Scammell 2004; Billing et al.
2007). The rs3800373 SNP is located in a region which
may alter stability and half-life of the mRNA molecule.
The SNP rs3800373 had associations with MDD and
MDD with Psychosis. The heterozygous genotype, AC, and
the minor allele homozygous CC were significantly more
frequent than expected based on Hardy–Weinberg assump-
tions of the North American Caucasian population and
previously published allelic and genotype frequencies
(Table 2; Haga et al. 2002). The HIV+MDD did not have
the same deviation from expected as the HIV-negative
MDD group. The MDD/Psych group had increased
Fig. 5 FKBP51 protein levels are altered in MDD groups compared
to control. Values were normalized to controls on their respective gels,
Normalized Fold-Actin = Fold-ActinPatient/Fold-ActinControlMean. The
area within the bar delineates the standard deviation about the mean
(μ ± σ). Kruskal–Wallace and Dunn’s multiple comparison test were
used to test for significance at p<0.05 (a). Representative blot is
showed in b
Fig. 6 Transcription factor binding sites and SNP locations on
FKBP5 gene. The genomic organization of the FKBP5 gene is
illustrated; exons are numbered with black bars; distance between
bars represents relative lengths of the introns. The locations of the
polymorphisms rs1360780 and rs3800373 are indicated by triangles,
and the locations of hormone-responsive elements are indicated with
diamonds (information from Hubler and Scammell 2004)
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frequency of the C allele compared with the North
American Caucasian population and the control group in
this study (Table 3).
In the, genotype frequencies of the Intron II polymor-
phism were significantly different in the MDD/Psych group
from North American Caucasian population. The AC and
CC genotypes were increased in the MDD/Psych as well as
significant increase in the minor, C, allele (Tables 2 and 3).
A possible confounder to this analysis is that the control
and the HIV populations differed from the Expected counts.
Discussion
The observation of unequal variance of transcriptional levels
of both FKBP4 and FKBP5 among the groups may indicate
a nonuniform distribution in the general population and
suggests that multiple mechanisms can be involved. None-
theless, the trends in variation in the MDD, MDD/Psychosis,
HIV, and HIV/MDD groups suggest that the interplay
between FKBP51 and FKBP52 in modulating the effects of
cortisol at the cellular level may be of consequence.
Our observation of higher FKBP5 gene transcription
levels in the MDD group that did not reach statistical
significance (Fig. 1), combined with previous reports that
FKBP5 is responsive to cortisol (Davies et al. 2002), likely
indicates increased expression in response to hypercortiso-
lemia in MDD. In HIV patients, immunophilin expression
is clearly elevated, probably in response to chronic
inflammation and microglial activation. Achim and Avra-
mut showed higher expression of the immunophilin
FKBP12 in the HIV-infected brain (Avramut and Achim
2003). If the immunophilins share similar promoter regions,
containing SP1 binding elements and CCAAT boxes, it
would make sense that immunophilins genes would be
upregulated by overlapping mechanisms.
FKBP5 transcript was much more variable in HIV+MDD
than HIV+, which could indicate two things. First, that
transcription of FKBP5 would be elevated in direct
response to hypercortisolemia, and second, that there is a
Table 2 Genotype frequencies for SNPs rs3800373 and rs1360780 of FKBP5 gene
rs3800373 rs1360780
Expected Observed χ2 Expected Observed χ2
AA AC CC AA AC CC p value AA AC CC AA AC CC p value
Control (n=13) 5.4 7 0.5 8 4 1 0.232 5.4 7 0.5 8 4 1 0.232
MDD (n=11) 5 6.5 0.5 7 2 2 0.015 5 6.5 0.5 7 2 2 0.015
MDD Psych (n=10) 4.6 6 0.5 2 6 2 0.037 4.6 6 0.5 2 6 2 0.037
HIV (n=9) 3.8 4.9 0.4 2 6 1 0.35 3.8 4.9 0.4 2 6 1 0.35
HIV MDD (n=8) 3.3 4.3 0.3 3 5 0 0.79 3.3 4.3 0.3 3 5 0 0.79
Genotypes were determined from genomic DNA by allelic discrimination assay described in “Materials and methods”. Based on the published
allelic frequencies for rs3800373: f(A)=0.688, f(C)=0.312 and for rs1360780: f(C)=0.758, f(T)=0.242, Expected genotype frequencies are
calculated based on Hardy–Weinberg equilibrium and compared to Observed genotypes for the study groups. χ2 analysis comparing Expected
with Observed values determines significant deviation in the patient groups from the population; significance is considered at p<0.05
Table 3 Allelic frequencies for SNPs rs3800373 and rs1360780 of FKBP5 gene
rs3800373 rs1360780
Expected Observed χ2 Expected Observed χ2
A C A C p value C T C T p value
Control (n=26) 18 8 20 6 0.371 20 6 17 9 0.215
MDD (n=22) 15 7 16 6 0.691 18 6 15 9 0.128
MDD Psych (n=20) 14 6 10 10 0.07 17 5 12 10 0.02
HIV (n=18) 12 6 10 8 0.225 14 4 9 9 0.011
HIV MDD (n=16) 11 5 11 5 0.997 12 4 11 5 0.51
Genotypes were determined from genomic DNA by allelic discrimination assay described in “Materials and methods”. Based on the published
allelic frequencies for rs3800373: f(A)=0.688, f(C)=0.312 and for rs1360780: f(C)=0.758, f(T)=0.242, Expected allele frequencies are calculated
based on group size and compared to Observed genotypes for the study groups. χ2 analysis comparing Expected with Observed values determines
significant deviation in the patient groups from the population; significance is considered at p<0.05
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subgroup of patients whose neurons did not increase
expression of FKBP5 concordantly to compensate resulting
in abnormally high GR signaling rendering them suscepti-
ble to the effects of the glucocorticoid cascade.
The SNP, rs1360780, located in Intron II, which contains
HREs, potential alternative promoter regions, and distal
enhancer elements (Hubler and Scammell 2004), had
genotype frequencies significantly different from expected
in control, MDD/Psychosis, and HIV. After genotyping the
FKBP5 gene for two SNPs, we found that rs3800373 CC
genotype is higher in the MDD and MDD/Psychosis group
(Table 2); this SNP is located in the 3′UTR of the mRNA
and could potentially affect protein translation. In Fig. 5,
we show higher protein levels of the FKBP5 gene product,
FKBP51, in portions of the MDD and MDD/Psychosis
groups as compared to control, while we did not find
significant changes in transcription levels; it may be that
this 3′UTR polymorphism affects translation efficiency. Our
data analysis methods, based on comparing to controls,
preclude determining whether higher protein amounts are
found in the C allele, but it would be an interesting next
step. Furthermore, new research on micro-RNAs show that
mRNA stability, based on micro-RNA binding in 3′UTRs,
affects the half-life of a particular transcript (Lai 2002); this
would be another possibility of yet another level of
modulation of cellular FKBP51 levels and thereby modu-
lation of glucocorticoid signaling and HPA axis function.
It should be noted that our design study was correlative
in analyzing gene and protein expressions in postmortem
analyses; the results will be correlative in nature. We cannot
determine whether FKBP51 and FKBP52 are dysregulated
in the frontal cortex as a process resulting from MDD or as
part of a process that led to MDD. Further, we do not know
the causes of the increase observed to correlate to HIV
infection; we hypothesize it to occur in neurons resulting
from chronic inflammatory signals from infected monocyte-
derived macrophages and microglia, from cytokine and
chemokine secretion, since FKBP51 and FKBP52 are
present in neurons of the frontal cortex, and neurons are
not infected with HIV, but rather respond to signals from
surrounding glia. However, it may be due to part of a
cellular “stress response” from shedded viral particles.
We hypothesized that FKBP51, as modulator of the
nuclear translocation of the GR, would be lower in MDD.
Instead, elevated FKBP51 at both the transcript and protein
levels correlates with MDD. However, FKBP52, the
adapter protein that facilitates active GR trafficking, was
variable in both directions, elevated, and decreased in
MDD and MDD/Psych. In contrast to FKBP5, FKBP4 fold
change was not significantly increased in HIV, but in
HIV+MDD. Perhaps immunophilins as a class of chaperone
and adapter proteins are upregulated during chronic
inflammation by a common mechanism, and if the agonist,
in this case FKBP5, is not significantly upregulated to
compensate for the increased ability of GR to be function-
ally active, cortical neurons would be rendered more
susceptible to the effects of glucocorticoids and the cascade
leading to the subtle pathologies of depression.
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